Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
This study has been completed.
Study NCT00004323 Information provided by National Center for Research Resources (NCRR)
First Received: October 18, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Aplastic Anemia
Additional conditions recognized in this trial
Anemia
Anemia, Aplastic
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Interventions listed in this trial
anti-thymocyte globulin
cyclophosphamide
cyclosporine
mesna
methotrexate
methylprednisolone
Additional drug interventions recognized in this trial
Antilymphocyte Serum
Cyclosporins
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Alkylating Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antiemetics
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Autonomic Agents
Central Nervous System Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Neuroprotective Agents
Nucleic Acid Synthesis Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
National Center for Research Resources (NCRR)
University of California, Los Angeles
Back to top of Main Content
